REG - C4X Discovery - Nick Ray Appointed as Chief Scientific Officer

C4X Discovery HoldingsAnnouncement

10/01/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230110:nRSJ1531Ma&default-theme=true

RNS Number : 1531M  C4X Discovery Holdings PLC  10 January 2023

C4X Discovery Holdings plc

 

("C4XD", "C4X Discovery" or the "Company")

 

C4XD Appoints Nick Ray as Chief Scientific Officer

 

10 January 2023 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug
Discovery company, announces the appointment of Nick Ray, PhD, as Chief
Scientific Officer with immediate effect.

 

Nick, a medicinal chemist by training who joined C4XD in 2016, is currently
Senior Vice President Drug Discovery, leading the medicinal chemistry,
structural analysis and computational chemistry/cheminformatics teams.  Nick
will continue to work closely with Clare Murray PhD, SVP Drug Discovery, to
advance the C4XD Drug Discovery portfolio from target selection through to
pre-clinical candidate generation and partnering, and with CTO, Charles
Blundell PhD, to continue development of our conformational analysis
technology, 4Sight.

 

Nick has more than 30 years' experience leading key programmes at large
multi-national companies including Rhône-Poulenc, Celltech and
Argenta/Charles River, in the therapeutic areas of oncology, respiratory
diseases, inflammation, CNS, pain and metabolic diseases.  Eight of these
programmes have progressed into the clinic to date. As head of the chemistry
department at Charles River's Harlow U.K. site, Nick was responsible for more
than 70 chemists, fostering both the importance of strong medicinal and
synthetic chemistry skills and championing professional development for his
team, winning the Royal Society of Chemistry Retrosynthesis competition in
2015.  He is a named inventor on over 75 patents and patent applications and
has published 21 papers and presentation abstracts.  Nick holds a PhD in
organic chemistry from the University of Birmingham, UK.

 

Clive Dix, CEO of C4XD, said: "Nick has played a key role in the growth of
C4XD and its reputation as a leading Drug Discovery company.  Since joining
the Company in 2016, his in-depth scientific expertise, particularly in
medicinal and computational chemistry, has enabled C4XD to develop a growing
portfolio of high quality small molecule Drug Discovery programmes, the very
core of our business.  Nick is highly respected both within C4XD and across
our industry, and more recently, he has made a significant contribution to the
commercial side of the business with the successful partnering of our IL-17A
Inhibitor programme with Sanofi and our NRF2 Activator programme with
AstraZeneca.  We are delighted to announce his promotion to Chief Scientific
Officer."

 

- Ends -

 

Contacts

 

 C4X Discovery Holdings
 Mo Noonan, Communications                                 +44 (0)787 6444977

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)            +44 (0)20 7886 2500
 Rupert Dearden (Corporate Broking)

 C4X Discovery Media - Consilium Strategic Communications
 Mary-Jane Elliott, Chris Gardner, Matthew Neal            +44 (0)203 709 5700

 

 

Notes to Editors:

 

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining
scientific expertise with cutting-edge Drug Discovery technologies to
efficiently deliver world leading medicines, which are developed by our
partners for the benefit of patients. We have a highly valuable and
differentiated approach to Drug Discovery through our enhanced DNA-based
target identification and candidate molecule design capabilities, generating
small molecule drug candidates across multiple disease areas including
inflammation, oncology, neurodegeneration and addictive disorders. Our
commercially attractive portfolio ranges from early-stage novel target
opportunities to late-stage Drug Discovery programmes ready for out-licensing
to partners and we have three commercially partnered programmes with one
candidate in clinical development.

 

We collaborate with leading pharmaceutical and life sciences companies to
enrich our expertise and take our assets through pre-clinical and clinical
development. Through early-stage revenue-generating licensing deals, we
realise returns from our high value pre-clinical assets which are reinvested
to maximise the value of our Drug Discovery portfolio.  For further
information see www.c4xdiscovery.com (http://www.c4xdiscovery.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAXFNEAPDEFA